The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics

This study, called REFORM, aims to find biomarkers that can predict how well erenumab works for migraine prevention. Erenumab is a costly migraine treatment, and not everyone responds to it. The study involves collecting clinical information, blood samples, MRI scans, and measuring response to a CGRP infusion to see if these factors can predict erenumab's effectiveness. This initial report describes the study's design, methods, and the basic characteristics of the participants involved.

• 1
  The study population had a high migraine burden, with most participants diagnosed with chronic migraine and using multiple acute and preventive medications.
• 2
  The baseline characteristics of the participants are similar to those seen in specialized headache clinics.
• 3
  Future publications will report the results of the investigations presented in this article.